
Transforming Single-Cell Discovery with Picodroplet Precision
SphereBio's platforms leverage advanced picodroplet microfluidics to streamline single-cell analysis, enabling faster, more accurate biologics discovery and development. With integrated, automated workflows and multiplexing capabilities, SphereBio solutions set a new standard in speed, scalability, and data confidence.
SphereBio delivers advanced solutions for single-cell analysis using its proprietary picodroplet microfluidic technology. Its platforms, including Cyto-Mine® and Cyto-Cellect®, streamline antibody discovery and cell line development with high-throughput, automation, and integrated clonality assessment—empowering faster, more confident biologics research.
Founded with a vision to transform biologics development, SphereBio is now a global leader in microfluidic-based single-cell technologies. Its tools are trusted by top pharma, biotech, and academic labs across 20+ countries, driving breakthroughs in drug discovery, oncology, and immunotherapy.
Model | Cyto-Mine® |
Applications | Antibody discovery, cell line development, single-cell screening |
Throughput | Up to 40 million picodroplets per run |
Processing Time | 24–48 hours (screening to clone identification) |
Droplet Volume | ~400 pL per droplet |
Discover the right solutions to accelerate your research with confidence!.
Picodroplet Microfluidics
Leverage proprietary picodroplet technology for ultra-high throughput single-cell screening, enabling millions of discrete cell-based assays per day with minimal reagent usage.
Integrated Single-Cell Workflow
Combines cell encapsulation, incubation, analysis, sorting, and dispensing into one seamless, automated platform—minimizing manual steps and maximizing efficiency.
Real-Time Clonality & Assay Data
Built-in imaging and analytical tools provide real-time insights into cell behavior, viability, and monoclonality—ensuring high-confidence selection for downstream processes.